Department of Respiratory Medicine, Xuhui District Central Hospital, Shanghai, China.
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9574-9581. doi: 10.26355/eurrev_201911_19452.
The aim of this study was to investigate the regulatory role of micro-ribonucleic acid (miR)-135a in monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats, and to analyze the possible regulatory mechanism.
A total of 30 Sprague-Dawley rats were randomly divided into three groups, including the blank control group, model group and miR-135a inhibitor intervention group. The right ventricular systolic pressure (RVSP) and right ventricle hypertrophy index (RVHI) were measured in rats of each group. Hematoxylin and eosin (HE) staining was adopted to detect the pathological changes in lung tissues of rats. Enzyme-linked immunosorbent assay (ELISA) was performed to measure the levels of interleukin-6 (IL-6) and IL-1β in lung tissues. Meanwhile, the messenger RNA (mRNA) and protein levels of β-catenin and glycogen synthase kinase-3β (GSK-3β) in lung tissues of rats were determined via Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Western blotting assay, respectively.
Compared with the blank control group, RVSP and RVHI increased significantly in the model group. The pathological morphology of the lung tissues was poor, and the content of IL-6 and IL-1β was markedly up-regulated in the model group. Meanwhile, the mRNA and protein levels of β-catenin and GSK-3β were notably elevated in the model group than the blank control group. In the miR-135a inhibitor intervention group, RVSP and RVHI decreased significantly, and the pathological morphology of lung tissues was evidently improved when compared with the blank control group. Furthermore, the content of IL-6 and IL-1β was remarkably reduced, and the mRNA and protein levels of β-catenin and GSK-3β were significantly declined in the miR-135a inhibitor intervention group.
MiR-135a inhibitor significantly alleviates inflammatory response in the lung tissues and ameliorates damage to the pathological morphology. The possible underlying mechanism may be associated with the β-catenin/GSK-3β signaling pathway.
本研究旨在探讨微小 RNA-135a(miR-135a)在野百合碱(MCT)诱导的大鼠肺动脉高压(PAH)中的调控作用,并分析其可能的调控机制。
将 30 只 Sprague-Dawley 大鼠随机分为三组,空白对照组、模型组和 miR-135a 抑制剂干预组。测量各组大鼠的右心室收缩压(RVSP)和右心室肥厚指数(RVHI)。采用苏木精-伊红(HE)染色法检测大鼠肺组织的病理变化。酶联免疫吸附试验(ELISA)检测肺组织中白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)的水平。同时,采用逆转录-聚合酶链反应(RT-PCR)和 Western blot 法分别检测大鼠肺组织中β-catenin 和糖原合成酶激酶-3β(GSK-3β)的信使 RNA(mRNA)和蛋白水平。
与空白对照组相比,模型组大鼠的 RVSP 和 RVHI 明显升高,肺组织的病理形态较差,IL-6 和 IL-1β 的含量明显升高。同时,模型组大鼠肺组织中β-catenin 和 GSK-3β 的 mRNA 和蛋白水平明显高于空白对照组。miR-135a 抑制剂干预组大鼠的 RVSP 和 RVHI 明显降低,与空白对照组相比,肺组织的病理形态明显改善。此外,miR-135a 抑制剂干预组大鼠 IL-6 和 IL-1β 的含量明显降低,β-catenin 和 GSK-3β 的 mRNA 和蛋白水平明显下降。
miR-135a 抑制剂可显著减轻肺组织的炎症反应,改善病理形态损伤。其可能的作用机制与β-catenin/GSK-3β 信号通路有关。